Does Gilead’s Raised Guidance and Earnings Surge Reinforce the Bull Case for GILD?

• Gilead Sciences recently reported strong third-quarter earnings with revenue of US$7.77 billion and net income of US$3.05 billion, raised its 2025 earnings guidance, continued share buybacks, and affirmed its quarterly dividend.
• An important insight is that the company achieved a very large increase in year-over-year net income and further tightened its product sales and EPS range upward for 2025, reflecting management confidence and ongoing operational momentum.
• We'll look at how Gilead's raised full-year guidance and robust earnings momentum may shift its long-term investment narrative and outlook.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Gilead Sciences Investment Narrative Recap

To be a shareholder in Gilead Sciences, you need to believe the company's strong portfolio in HIV, oncology, and liver disease, combined with a robust pipeline and prudent capital allocation, can offset regulatory, pricing, and generic competition risks. The recent earnings beat and raised guidance support the short-term catalyst of accelerating EPS growth, but do not materially shift the key risk: Gilead’s long-term vulnerability to pricing pressure and reliance on HIV revenues.

Among recent announcements, Gilead’s revised 2025 guidance, lifting product sales and EPS expectations, is the most relevant here. This move reinforces management’s current confidence in operational momentum, underpinned by strong net income growth and persistent share buybacks, which directly feed into key catalysts around earnings growth and shareholder returns.

Yet, in contrast, investors should be aware of ongoing risks related to policy-driven pricing pressure on Gilead’s core HIV franchise that could ...

Read the full narrative on Gilead Sciences (it's free!)

Gilead Sciences' outlook anticipates $32.3 billion in revenue and $10.0 billion in earnings by 2028. This is based on an annual revenue growth rate of 3.8% and reflects an increase in earnings of $3.7 billion from the current $6.3 billion level.

Uncover how Gilead Sciences' forecasts yield a $127.23 fair value, a 4% upside to its current price.

Exploring Other Perspectives

The highest analyst estimates give a much more optimistic outlook, forecasting US$33.9 billion in revenue and US$10.8 billion in earnings by 2028, centered on rapid new drug adoption. If you’re considering Gilead, remember that these optimistic views depend on stronger product launches and less pricing erosion than the consensus expects. Think about how recent news might alter either view and why opinions across the market can vary so much, even when all analysts see the same headlines.

Explore 11 other fair value estimates on Gilead Sciences - why the stock might be worth 23% less than the current price!

Build Your Own Gilead Sciences Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 38 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com